- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03595878
Trial of Parotid Sparing Whole Brain Radiation
Randomized Trial of Parotid Sparing Whole Brain Radiation
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina at Chapel Hill, Department of Radiation Oncology
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest Baptist Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients to be treated with WBRT using 3-dimensional conformal RT in 10-15 fractions to a total dose of 30-35 Gy for any diagnosis other than elective treatment of potentially subclinical intracranial disease.
No prior radiation that would have exposed the parotids to a significant level of radiation (estimated >10 Gy mean parotid dose). Patients receiving prior stereotactic radiosurgery for brain metastasis are eligible for inclusion in this trial as this form of radiation is highly conformal and exposes the parotids to minimal (estimated <1 Gy) radiation.
- Patients enrolling on the observational arm may have started their current course of whole brain radiation therapy within 5 days prior to completing the baseline screening questionnaire and consenting to study.
- Greater than or equal to 18 years of age (no upper age limit).
- Raw xerostomia score < 40 / 80 on the initial screening xerostomia questionnaire. This is calculated by adding up the values from questions 1-8.
- Initial xerostomia questionnaire and informed consent obtained within the required time frame (≤ 30 days before RT start for interventional arm; ≤ 5 days after RT start for observational arm).
Exclusion Criteria:
- Patients receiving WBRT without the use of a CT- or MRI-based planning simulation.
- Patients receiving WBRT with the use of intensity-modulated radiation therapy.
- Patient receiving WBRT as elective treatment of potentially subclinical intracranial disease (e.g., WBRT for prophylactic cranial irradiation of small cell lung cancer).
- Patients physically unable to communicate by paper or phone to complete the study survey.
- Prisoners.
- Pregnant patients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Randomized Arm - Control Group
Patients randomized to this group will receive standard WBRT.
|
Standard Whole Brain Radiation Therapy
|
Experimental: Randomized Arm - Intervention Group
Patients randomized to this group will receive parotid sparing WBRT.
|
Whole Brain Radiation Therapy with avoidance of the parotid glands
|
No Intervention: Observational Arm
Patients enrolled in this arm will be treated per their treating physician's choice.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Xerostomia One Month After Completion of Treatment
Time Frame: Up to 45 days
|
Between baseline and 1 month after the treatment xerostomia symptoms were assessed, in 2 randomized groups namely Arm A and Arm B. Xerostomia symptoms were assessed using the patient-reported study xerostomia questionnaire. The questionnaire includes 8 questions, and each question score changes between 0 to 10. The increasing value represents worse xerostomia symptoms. No xerostomia symptom= 0 and highest xerostomia symptom=10. The total score will be on a scale from 0-80 (8 categories with a maximum score of 10). Changes in xerostomia symptoms in each arm were tabulated. Positive values represent increased xerostomia symptoms and negative values represent decreasing xerostomia symptoms and no difference is no change. |
Up to 45 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom From Relapse
Time Frame: Up to 6 months
|
The number of subjects with marginal cervical spine relapse in each randomization arm.
|
Up to 6 months
|
Xerostomia Based on Radiotherapy Treatment Fields- One Month After the Treatment
Time Frame: Up to 45 days
|
Between baseline and 1 month after the treatment xerostomia symptoms were assessed and tabulated based on the whole brain radiotherapy (WBRT) technique.
The Standard WBRT Group includes both randomized (Group A) and non-randomized (Group C) subjects who received WBRT.
The Parotid Sparing WBRT Group includes subjects who were randomized and received Parotid Sparing WBRT (Group B).
Xerostomia symptoms were assessed using the patient-reported study xerostomia questionnaire.
The questionnaire includes 8 questions, and each question score changes between 0 to 10.
The increasing value represents worse xerostomia symptoms.
No xerostomia symptom= 0 and highest xerostomia symptom=10.
The total score will be on a scale from 0-80 (8 categories with a maximum score of 10).
Changes were tabulated as: Positive values represent worsened xerostomia symptoms, and both negative values and no change values represent did not worsen.
|
Up to 45 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Colette Shen, University of North Carolina at Chapel Hill, Department of Radiation Oncology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LCCC 1802
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Xerostomia
-
Cathrine RahbekDanish Cancer Society; DLHM - Danish Society for Mouth and Throat Cancer; Danish...Active, not recruitingXerostomia Following Radiotherapy | Xerostomia Following in Neck Ore Head After CancersurgeryDenmark
-
Bedford Hospital NHS TrustUnknownXerostomia | Xerostomia Due to Radiotherapy | Xerostomia Due to Hyposecretion of Salivary Gland
-
Institute of Oncology LjubljanaUniversity Medical Centre Ljubljana; University of Ljubljana; Blood Transfusion...Not yet recruitingXerostomia Following RadiotherapySlovenia
-
Catholic University of the Sacred HeartSunstar Italiana SRL.CompletedXerostomia | Xerostomia Following RadiotherapyItaly
-
Qazvin University Of Medical SciencesImam Khomeini HospitalCompletedRadiation-Induced XerostomiaIran, Islamic Republic of
-
Institut de Terapia Regenerativa TissularUnknownXerostomia Due to RadiotherapySpain
-
Laboratoires CARILENEDERMSCAN-PHARMASCAN GROUP in charge of data analysisCompleted
-
MeiraGTx, LLCActive, not recruitingRadiation-induced XerostomiaUnited States, Canada
-
Thomas KuhntVerband Deutscher DruckkammerzentrenTerminatedRadiation-induced XerostomiaGermany
Clinical Trials on Standard WBRT
-
Royal Adelaide HospitalCompletedNeoplasm Metastasis | Brain NeoplasmAustralia
-
National Cancer Centre, SingaporeSingapore General Hospital; Singhealth Duke-NUS Oncology Academic Clinical...Active, not recruiting
-
National Taiwan University HospitalUnknownMetastatic Malignant Neoplasm to BrainTaiwan
-
Melanoma and Skin Cancer Trials LimitedUniversity of Oxford; Trans Tasman Radiation Oncology GroupActive, not recruitingMetastatic MelanomaNorway, Australia, United Kingdom
-
Betta Pharmaceuticals Co., Ltd.RecruitingNon Small Cell Lung Cancer | Brain MetastasesChina
-
Juergen DebusHeidelberg UniversityCompletedSCLC | Brain MetastasesGermany
-
Thomas Jefferson UniversityUnknownCerebral Metastases PatientsUnited States
-
Chang Gung Memorial HospitalRecruiting
-
Chang Gung Memorial HospitalRecruitingBrain Metastasis | Brain MetastasesTaiwan
-
Chang Gung Memorial HospitalRecruitingBrain Metastasis | Non-Small-Cell Lung Cancer (NSCLC)Taiwan